{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:27Z","timestamp":1787028627929,"version":"build-2736575974"},"reference-count":19,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We report the first case of Daratumumab interference of allogeneic crossmatch tests repeatedly causing aberrant false-positive results, which inadvertently delayed transplant for a waitlisted renal patient with multiple myeloma. Daratumumab is an IgG1\u03ba human monoclonal antibody commonly used to treat multiple myeloma, characterized by cancerous plasma cells and often leads to renal failure requiring kidney transplant, by depleting CD38-expressing plasma cells. In this case study, the patient had end-stage renal disease secondary to multiple myeloma and was continuously receiving Daratumumab infusions. The patient did not have any detectable antibodies to human leukocyte antigens but repeatedly had unexpected positive crossmatch by the flow cytometry-based method with 26 of the 27 potential deceased organ donors, implying donor-recipient immunological incompatibility. However, further review and analysis suggested that the positive crossmatches were likely false-positive as a result of interference from Daratumumab binding to donor cell surface CD38 as opposed to the presence of donor-specific antibodies. The observed intensity of the false-positive crossmatches was also highly variable, potentially due to donor- and\/or cell-dependent expression of CD38. The variability of CD38 expression was, therefore, for the first time, characterized on the T and B cells isolated from various tissues and peripheral blood of 78 individuals. Overall, T cells were found to have a lower CD38 expression profile than the B cells, and no significant difference was observed between deceased and living individuals. Finally, we show that a simple cell treatment by dithiothreitol can effectively mitigate Daratumumab interference thus preserving the utility of pre-transplant crossmatch in multiple myeloma patients awaiting kidney transplant.<\/jats:p>","DOI":"10.3390\/jcm11206059","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T02:29:46Z","timestamp":1665973786000},"page":"6059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-2537","authenticated-orcid":false,"given":"Chak-Sum","family":"Ho","sequence":"first","affiliation":[{"name":"Gift of Hope Organ & Tissue Donor Network, Itasca, IL 60143, USA"},{"name":"Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI 48824, USA"},{"name":"Gift of Life Michigan, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle R.","family":"Putnam","sequence":"additional","affiliation":[{"name":"Gift of Life Michigan, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"Peiter","sequence":"additional","affiliation":[{"name":"Gift of Life Michigan, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-7061","authenticated-orcid":false,"given":"Walter F.","family":"Herczyk","sequence":"additional","affiliation":[{"name":"Gift of Life Michigan, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Gift of Life Michigan, Ann Arbor, MI 48108, USA"},{"name":"Biomedical Laboratory Diagnostics Program, College of Natural Science, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Campagnaro","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Woodside","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-9747","authenticated-orcid":false,"given":"Matthew F.","family":"Cusick","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medicine, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic advancements in multiple myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"17","author":"Touzeau","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.humimm.2020.06.009","article-title":"Physical Crossmatching vs Virtual Crossmatching: The end of an era? or Why give up a good thing?","volume":"81","author":"Sullivan","year":"2020","journal-title":"Hum. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2007.01667.x","article-title":"Pretransplant risk assessment in renal allograft recipients using virtual crossmatching","volume":"7","author":"Bielmann","year":"2007","journal-title":"Am. J. Transpl."},{"key":"ref_9","first-page":"4534898","article-title":"False Positive B-Cells Crossmatch after Prior Rituximab Exposure of the Kidney Donor","volume":"2016","author":"Desoutter","year":"2016","journal-title":"Case Rep. Transpl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101360","DOI":"10.1016\/j.trim.2020.101360","article-title":"Impact of rituximab on the T-cell flow cytometric crossmatch","volume":"64","author":"Doss","year":"2021","journal-title":"Transpl. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: A (r) evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humimm.2015.09.029","article-title":"Variable HLA expression on deceased donor lymphocytes: Not all crossmatches are created equal","volume":"76","author":"Badders","year":"2015","journal-title":"Hum. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001818","article-title":"Of Cells and Microparticles: Assets and Liabilities of HLA Antibody Detection","volume":"102","author":"Liwski","year":"2018","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Reid, M.E., Lomas-Francis, C., and Olsson, M.L. (2012). The Blood Group Antigen Factsbook, Elsevier\/AP. [3rd ed.].","DOI":"10.1016\/B978-0-12-415849-8.00029-6"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use","volume":"30","author":"Kwun","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:44Z","timestamp":1760144024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":19,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11206059"],"URL":"https:\/\/doi.org\/10.3390\/jcm11206059","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202209.0161.v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}